RESUMEN
Objectives: The recent introduction of direct-acting antiviral agents (DAAs) which can eliminate Hepatitis C virus (HCV) had revolutionized the treatment of HCV infections also in a complex clinical setting such as the patients with rheumatoid arthritis (RA). HCV elimination is also opportune due to the availability of more efficient immunosuppressive drugs, whose effect on the course of HCV infection is largely unknown.Methods: Consensus process was endorsed by the Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) to review the available evidence and produce practical, hospital-wide recommendations. The consensus panel consisted of 18 infectious diseases consultants, 20 rheumatologists and one clinical epidemiologist, who used the criteria of the Oxford Centre for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations.Results: A core-set of statements about management of patients with RA and infection by HCV have been developed to help clinicians in their clinical practice.Conclusions: A screening for HCV should be performed in all RA patients and it is mandatory before starting an immunosuppressive therapy. Finally, a DAA treatment should be considered in all HCV-infected patients.Significance and InnovationsHCV antibodies should be investigated at the time of diagnosis of RA and, in any case, before starting immunosuppressive therapy with disease-modifying antirheumatic drugs (DMARDs).HCV eradication with DAA should be attempted as soon as possible, depending on patient conditions allowing a continuous oral treatment lasting 8-12 weeksConventional and biological DMARDs are allowed in patients with HCV infection, but they should be used cautiously in presence of advanced liver disease.
Asunto(s)
Antivirales/uso terapéutico , Artritis Reumatoide/complicaciones , Hepatitis C Crónica/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Antirreumáticos/administración & dosificación , Antirreumáticos/uso terapéutico , Antivirales/administración & dosificación , Artritis Reumatoide/tratamiento farmacológico , Consenso , Medicina Basada en la Evidencia , Hepatitis C Crónica/complicaciones , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , ItaliaRESUMEN
OBJECTIVES: Hepatitis B (HBV) infection, which is prevalent worldwide, is also frequently seen in patients with rheumatoid arthritis (RA). The Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) endorsed a national consensus process to review the available evidence on HBV management in RA patients and to produce practical, hospital-wide recommendations. METHODS: The consensus panel consisted of infectious disease consultants, rheumatologists and epidemiologists and used the criteria of the Oxford Center for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations. RESULTS: A core-set of statements has been developed to help clinicians in the management of patients with RA and HBV infection. Vaccination and prophylaxis of RA patients treated with biological drugs have been also discussed. CONCLUSIONS: HBV infection is not rare in clinical practice; a screening for HBV in all patients with early arthritis is not universally accepted, while it is considered mandatory before starting any immunosuppressive or hepatotoxic treatment. In fact, a specific risk, associated with the use of biologic treatments, exists for patients with HBV infection, although longitudinal studies of viral reactivation are generally reassuring. RA patients with HBV infection should be referred to the hepatologist and correctly classified into active or inactive carriers. Patients with active hepatitis B should undergo antiviral treatment before starting immunosuppressive treatments. Occult HBV carriers should be monitored or receive prophylaxis on the basis of the risk of reactivation associated with the administered treatment.
Asunto(s)
Antivirales/uso terapéutico , Artritis Reumatoide/epidemiología , Hepatitis B/tratamiento farmacológico , Hepatitis B/epidemiología , Guías de Práctica Clínica como Asunto , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/terapia , Comorbilidad , Femenino , Hepatitis B/diagnóstico , Hepatitis B Crónica/diagnóstico , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/epidemiología , Humanos , Italia , Masculino , Pronóstico , Medición de Riesgo , Índice de Severidad de la Enfermedad , TerapéuticaRESUMEN
BACKGROUND: The incidence of Kaposi's sarcoma (KS), an AIDS-related malignancy, has dramatically decreased in the Highly Active Anti-retroviral Therapy (HAART) era. However, KS remains the second most frequent tumor in HIV-infected patients worldwide and has become the most common cancer in the sub-Saharan Africa. Experimental studies have demonstrated a direct anti-neoplastic effect of HAART, and overall of protease inhibitors (PIs), on KS. CASE REPORT: We describe five cases of KS in HIV-infected patients on HAART regimen, containing PIs as atazanavir/r (ATV/r), darunavir/r (DRV/r), lopinavir/r (LPV/r) and fosamprenavir (fAMP/r). CONCLUSION: Clinical and experimental observations support the hypothesis that PIs may play an important role in prevention and treatment of KS. In our study, the treatment with PIs of recent generation was not protective against the development of KS. Therefore, it could be necessary to re-evaluate the therapeutic effects of PIs and their role in the development and treatment of KS in HIV-infected patients.
Asunto(s)
Infecciones por VIH/complicaciones , Inhibidores de la Proteasa del VIH/farmacología , Sarcoma de Kaposi/etiología , Adulto , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Terapia Antirretroviral Altamente Activa , Recuento de Linfocito CD4 , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Inhibidores de la Proteasa del VIH/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Sarcoma de Kaposi/tratamiento farmacológico , Sarcoma de Kaposi/patología , Sarcoma de Kaposi/prevención & control , Resultado del Tratamiento , Carga Viral , Adulto JovenRESUMEN
BACKGROUND/AIM: HIV infection is a risk factor for re-activation of latent tubercolosis infection (LTBI). In recent years new blood tests for the detection of TB infection have been developed: Quantiferon TB Gold in Tube and TSPOT TB, which are interferon-γ releasing assays (IGRAs), have improved the identification of LTBI. In our study we have compared IGRAs and TST in HIV-positive patients with different settings of immunodeficiency. PATIENTS AND METHODS: 98 consecutive HIV patients were recruited. They underwent a blood draw, a chest radiography and a tuberculin skin test. The HIV infection setting was detected and IGRAs were carried-out. Five patients showed a complete correspondence of TST, TSPOT-TB and QFT-IT. Discordant results were observed in patients testing positive to IGRAs but negative to TST. Only 2 patients showed positive TST and negative IGRAs. CONCLUSION: Our study showed a poor concordance between tuberculin skin test and IGRAs, mainly in patients with a low CD4 cell count.
Asunto(s)
Infecciones por VIH , Ensayos de Liberación de Interferón gamma , Tuberculosis Latente/diagnóstico , Prueba de Tuberculina , Adulto , Anciano , Terapia Antirretroviral Altamente Activa , Recuento de Linfocito CD4 , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Infecciones por VIH/virología , Humanos , Ensayos de Liberación de Interferón gamma/normas , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Prueba de Tuberculina/normas , Carga Viral , Adulto JovenRESUMEN
Chronic kidney disease is a major comorbidity in patients affected by HIV infection. In addition, the introduction of new antiretroviral agents that interact with creatinine transporters is raising some concerns. In this review we analyze the currently available data about three new antiretroviral drugs and one new pharmacokinetic enhancer. Three of them (rilpivirine, cobicistat, dolutegravir) have shown some interactions with renal function, while tenofovir alafenamide fumarate reduces the plasmatic concentration of the parent drug. The future use of tenofovir alafenamide seems to be encouraging in order to reduce the renal interaction of tenofovir. Rilpivirine, cobicistat, and dolutegravir reduce the tubular secretion of creatinine, inducing a decrease of estimated glomerular filtration rate according to creatinine. Rilpivirine and dolutegravir block the uptake of creatinine from the blood, inhibiting organic cation transporter 2, and cobicistat interacts with the efflux inhibiting multidrug and toxin extrusion protein 1. This effect can then be considered a "reset" of the estimated glomerular filtration rate according to creatinine. However, clinicians should carefully monitor renal function in order to identify possible alterations suggestive of a true renal functional impairment. Owing to the interference of these drugs with creatinine secretion, an alternative way of estimation of glomerular filtration rate would be desirable. However, at the moment, other methods of direct glomerular filtration rate measurement have a high impact on the patient, are not readily available, or are not reliable in HIV patients. Consequently, use of classic formulas to estimate glomerular filtration rate is still recommended. Also, tubular function needs to be carefully monitored with simple tests such as proteinuria, phosphatemia, urinary excretion of phosphate, normoglycemic glycosuria, and excretion of uric acid.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Pruebas de Función Renal , Monitoreo Fisiológico , Adenina/efectos adversos , Adenina/análogos & derivados , Adenina/uso terapéutico , Fármacos Anti-VIH/efectos adversos , Carbamatos/efectos adversos , Carbamatos/uso terapéutico , Cobicistat , Infecciones por VIH/fisiopatología , Compuestos Heterocíclicos con 3 Anillos/efectos adversos , Compuestos Heterocíclicos con 3 Anillos/uso terapéutico , Humanos , Nitrilos/efectos adversos , Nitrilos/uso terapéutico , Organofosfonatos/efectos adversos , Organofosfonatos/uso terapéutico , Oxazinas , Piperazinas , Piridonas , Pirimidinas/efectos adversos , Pirimidinas/uso terapéutico , Rilpivirina , Tenofovir , Tiazoles/efectos adversos , Tiazoles/uso terapéuticoRESUMEN
INTRODUCTION: Translation of the evidence regarding the protective role of highly active antiretroviral therapy (HAART) on HIV sexual transmission rates into sexual behaviour patterns of HIV-infected subjects remains largely unexplored. This study aims to describe frequency of self-reported condom use among women living with HIV in Italy and to investigate the variables associated with inconsistent condom use (ICU). METHODS: DIDI (Donne con Infezione Da HIV) is an Italian multicentre study based on a questionnaire survey performed during November 2010 and February 2011. Women-reported frequency of condom use was dichotomized in "always" versus "at times"/"never" (ICU). RESULTS: Among 343 women, prevalence of ICU was 44.3%. Women declared a stable partnership with an HIV-negative (38%) and with an HIV-positive person (43%), or an occasional sexual partner (19%). Among the 194 women engaged in a stable HIV-negative or an occasional partnership, 51% reported fear of infecting the partner. Nonetheless, 43% did not disclose HIV-positive status. Less than 5% of women used contraceptive methods other than condoms. At multivariable analysis, variables associated with ICU in the subgroup of women with a stable HIV-negative or an occasional HIV-unknown partner were: having an occasional partner (AOR 3.51, 95% confidence interval [CI] 1.44-8.54, p=0.005), and reporting fear of infecting the sexual partner (AOR 3.20, 95% CI 1.43-7.16, p=0.004). Current use of HAART together with virological control in plasma level did not predict ICU after adjusting for demographic, behavioural and HIV-related factors. With regard to socio-demographic factors, lower education was the only variable significantly associated with ICU in the multivariate analysis (AOR 2.27, 95% CI 1.07-4.82, p=0.03). No association was found between high adherence to HAART and ICU after adjusting for potential confounders (AOR 0.89, 95% CI 0.39-2.01, p=0.78). CONCLUSIONS: Currently in Italy, the use of HAART with undetectable HIV RNA in plasma as well as antiretroviral adherence is not associated with a specific condom use pattern in women living with HIV and engaged with a sero-discordant or an HIV-unknown partner. This might suggest that the awareness of the protective role of antiretroviral treatment on HIV sexual transmission is still limited among HIV-infected persons, at least in this country.
Asunto(s)
Condones/estadística & datos numéricos , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Conducta Sexual , Adulto , Femenino , Humanos , Italia , Encuestas y CuestionariosRESUMEN
The highly active antiretroviral therapy (HAART) can cause a metabolic syndrome consisting of lipodystropy/lipoatrophy, dyslipidemia, and type 2 diabetes mellitus with an increased cardiovascular risk. The pathogenetic bases of HAART-associated lipodystrophy are poorly known. A genetic screen was used to evaluate proteins that are modulated in HIV-1-infected patients with or without lipodystrophy syndrome, that are routinely treated with HAART regimens. The most significant modulation was represented by FAP48 expression. Stable over-expression of FAP48 was able to alter, in vitro, adipogenesis, acting both on calcineurin and glucocorticoid pathways. Finally, we demonstrated that FAP48 over-expression was able to influence the capacity of some HIV drugs, Saquinavir and Efavirenz, but not Stavudine, Amprenavir, and Indinavir to inhibit adipocyte formation. In conclusion, this molecule could be a potential target for novel therapeutic approaches to the HAART related lipodystrophy in HIV patients.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Adipocitos/efectos de los fármacos , Síndrome de Lipodistrofia Asociada a VIH/metabolismo , Proteínas Adaptadoras Transductoras de Señales/genética , Adipocitos/metabolismo , Adipocitos/patología , Alquinos , Animales , Terapia Antirretroviral Altamente Activa/efectos adversos , Benzoxazinas/efectos adversos , Benzoxazinas/farmacología , Calcineurina/genética , Calcineurina/metabolismo , Carbamatos/efectos adversos , Carbamatos/farmacología , Diferenciación Celular/efectos de los fármacos , Línea Celular , Ciclopropanos , Furanos , Expresión Génica/efectos de los fármacos , Glucocorticoides/metabolismo , VIH-1/efectos de los fármacos , VIH-1/fisiología , Síndrome de Lipodistrofia Asociada a VIH/inducido químicamente , Humanos , Indinavir/efectos adversos , Indinavir/farmacología , Ratones , Saquinavir/efectos adversos , Saquinavir/farmacología , Transducción de Señal/efectos de los fármacos , Estavudina/efectos adversos , Estavudina/farmacología , Sulfonamidas/efectos adversos , Sulfonamidas/farmacología , TransfecciónRESUMEN
Highly active antiretroviral therapy (HAART therapy) for HIV-1 infection has significantly increased the survival and quality of life of patients with this disease. However, in several epidemiological studies the onset of metabolic syndrome is a phenomenon reported to be extremely frequent. In the present study, genes involved in the molecular cascade responsible for the alteration of fat tissue and of lipid and glucose metabolism in patients with HIV-1 infection treated with antiretroviral therapy were identified. Towards this goal, hybridization using Atlas cDNA Expression Arrays allowed simultaneous monitoring of the expression levels of approximately 250 genes and identification of a panel of changes in relation to different therapeutic groups and in the presence of metabolic syndrome, with some genes being up-regulated, while others are down-regulated in the different subgroups of patients. The results of this analysis have shown a panel of transcriptional changes associated with oxidative stress mechanisms that provide a basis for further studies on understanding of mechanisms that, in vivo, are the foundation the metabolic disorders in patients with HIV infection.
Asunto(s)
Fármacos Anti-VIH/farmacología , Terapia Antirretroviral Altamente Activa/efectos adversos , Perfilación de la Expresión Génica , Infecciones por VIH/genética , VIH-1 , Síndrome Metabólico/inducido químicamente , Transcripción Genética/efectos de los fármacos , Adipogénesis/efectos de los fármacos , Adipogénesis/genética , Fármacos Anti-VIH/efectos adversos , Proteínas Potenciadoras de Unión a CCAAT/metabolismo , ADN Complementario/genética , Inhibidores de la Proteasa del VIH/efectos adversos , Inhibidores de la Proteasa del VIH/farmacología , Síndrome de Lipodistrofia Asociada a VIH/inducido químicamente , Síndrome de Lipodistrofia Asociada a VIH/epidemiología , Síndrome de Lipodistrofia Asociada a VIH/metabolismo , Humanos , Incidencia , Síndrome Metabólico/epidemiología , Síndrome Metabólico/genética , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/genética , Receptores Activados del Proliferador del Peroxisoma/metabolismoRESUMEN
In the present study, we investigated the ability of anti-HIV drugs to interfere with normal cell cycle progression and to induce oxidative stress by perturbing the redox environment. Our results provide evidence that anti-HIV drugs have a differential effect on adipocyte cell cycle and differentiation, being able to modify the response to oxidative stress through an increase of reactive oxygen species (ROS) that compromises the induction of phase-2 and antioxidant enzymes. In detail, saquinavir, efavirenz, and stavudine exert antiadipogenic influences on the model 3T3-L1 cell line, perturbing the oxidative response and inducing of apoptosis. When considered together, the effects of anti-HIV drugs on 3T3-L1 pre adipocytes are distinct but commonly antiadipogenic, thus suggesting another additional possible mechanism by which antiretroviral therapies could contribute to lipoatrophy.
Asunto(s)
Adipocitos/efectos de los fármacos , Adipogénesis/efectos de los fármacos , Fármacos Anti-VIH/farmacología , Apoptosis/efectos de los fármacos , 1-Metil-3-Isobutilxantina/farmacología , Células 3T3-L1/efectos de los fármacos , Células 3T3-L1/metabolismo , Adipocitos/patología , Alquinos , Animales , Benzoxazinas/farmacología , Carbamatos/farmacología , Ciclo Celular/efectos de los fármacos , Ciclopropanos , Dexametasona/farmacología , Inducción Enzimática/efectos de los fármacos , Furanos , Síndrome de Lipodistrofia Asociada a VIH/inducido químicamente , Síndrome de Lipodistrofia Asociada a VIH/patología , Hemo-Oxigenasa 1/biosíntesis , Hemo-Oxigenasa 1/genética , Indinavir/farmacología , Insulina/farmacología , Proteínas de la Membrana/biosíntesis , Proteínas de la Membrana/genética , Ratones , NAD(P)H Deshidrogenasa (Quinona)/biosíntesis , NAD(P)H Deshidrogenasa (Quinona)/genética , Oxidación-Reducción , Estrés Oxidativo , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Saquinavir/farmacología , Estavudina/farmacología , Sulfonamidas/farmacología , Superóxido Dismutasa/biosíntesis , Superóxido Dismutasa/genética , Superóxido Dismutasa-1RESUMEN
BACKGROUND: The hypothesis that fosamprenavir-including highly active antiretroviral therapy (HAART) regimens would be associated with few metabolic and hepatic side-effects was investigated. PATIENTS AND METHODS: An observational single-arm retrospective study was set up on a cohort of 139 human immunodeficiency virus (HIV)-infected patients, followed up at A.O.R.N. Cotugno Hospital, Naples, Italy, treated with antiretroviral regimens including fosamprenavir, in order to evaluate the safety of these regimens in relationship to hepatic and metabolic side-effects, also considering co-morbidities and other risk factors. RESULTS: Only seven patients met the criteria to reach the primary end-point (grade ≥ 3 adverse event) and none of them discontinued HAART therapy during the follow-up period. Eighty percent of the patients reached viral load <50 cp/µl at 48 weeks of observation. At the end of follow-up, no patient with fasting serum total cholesterol and/or fasting serum triglycerides above grade 3 was found, while 1 out of 114 (0.88%) cases presented aspartate transaminase and alanine transaminase ≥ grade 3 and 1 out of 114 (0.88%) cases had fasting serum glucose ≥ grade 3. One out of 137 patients developed a malignant neoplasm (0.73%) and 4 (2.92%) displayed newly diagnosed hypertension. CONCLUSION: Fosamprenavir-based regimens caused a low number of serious metabolic adverse events during a 48 week follow-up period, with a low incidence of co-morbidities and satisfying results in terms of viro-immunological response including for patients with already existing co-morbidities requiring other therapies.
Asunto(s)
Carbamatos/efectos adversos , Infecciones por VIH/tratamiento farmacológico , VIH-1 , Hipertensión/epidemiología , Neoplasias/epidemiología , Organofosfatos/efectos adversos , Sulfonamidas/efectos adversos , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Glucemia , Carbamatos/uso terapéutico , Colesterol/sangre , Estudios de Cohortes , Comorbilidad , Femenino , Furanos , Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiología , Hepatitis C Crónica/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Organofosfatos/uso terapéutico , Estudios Retrospectivos , Sulfonamidas/uso terapéutico , Triglicéridos/sangreRESUMEN
BACKGROUND: The introduction of highly active antiretroviral therapy reduced HIV-associated morbidity and mortality, at the cost of adverse metabolic effects that increase cardiovascular risk. The aim of this study was to evaluate the impact of exposure to protease inhibitors (PI) compared with exposure to non-nucleoside reverse transcriptase inhibitors (NNRTI) on carotid intima-media thickness (IMT) and blood flow velocity and to measure vascular involvement over a 2-year follow-up in HIV-infected patients treated with PI. METHODS: Thirty-five HIV-infected patients treated with PI (group I) and 15 patients treated with NNRTI (group II) underwent epiaortic vessel ultrasonography. The same evaluation was obtained in a group of 20 healthy subjects. After 20 +/- 2 months, 22 patients of group I were re-evaluated and the follow-up data were compared with those obtained at baseline. RESULTS: The ANOVA test showed a significant difference among the three groups for IMT and flow velocities. Bonferroni analyses showed significant differences in IMT and flow velocities in group I vs group II vs controls: IMT of the right common carotid artery was 0.742 +/- 0.135 mm in group I vs 0.642 +/- 0.131 mm in group II (p < 0.05) and 0.616 +/- 0.069 mm in controls (p = 0.002); IMT of left common carotid artery was 0.720 +/- 0.108 vs 0.659 +/- 0.066 mm (p < 0.05) and 0.640 +/- 0.081 mm (p < 0.01), respectively. There were no differences in group II vs healthy subjects. At follow-up examinations of group I, no significant differences were observed in both IMT and blood flow velocity when compared with baseline values. CONCLUSIONS: The HIV-infected patients treated with PI show earlier vascular involvement as compared to those treated with NNRTI and to healthy subjects with similar distribution of cardiovascular risk factors. However, such damage seems to have no significant progression over a 2-year follow-up in HIV-infected patients treated with PI. These data emphasize the need for follow-up studies assessing whether these changes are predictive of adverse cardiac events.
Asunto(s)
Arterias Carótidas/efectos de los fármacos , Arterias Carótidas/patología , Inhibidores de la Proteasa del VIH/farmacología , Inhibidores de la Proteasa del VIH/uso terapéutico , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Seropositividad para VIH/tratamiento farmacológico , Túnica Íntima/efectos de los fármacos , Túnica Íntima/patología , Túnica Media/efectos de los fármacos , Túnica Media/patología , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The pathogenetic bases of HAART-associated lipodystrophy are still poorly known, even if it is clear that adipose tissue and its metabolism are sensitive to antiretroviral therapy alone and/or in combination with HIV infection. The NEDD8 system is essential for the regulation of protein degradation pathways involved in cell cycle progression, morphogenesis and tumorigenesis. We investigated the possible involvement of NEED8 in adipogenesis and, consequently, in HIV-related lipodystrophy. One hundred HIV-1-infected patients were included in the study. Using an in vitro model of adipogenesis we evaluated the effects on adipogenesis of the forced expression of NEDD8 together with efavirenz, stavudine, saquinavir, amprenavir and indinavir, belonging to the three main classes of anti-HIV medications. We showed that NEDD8 expression level is higher in the peripheral blood of HIV patients developing lipodystrophy. Coherently, forced expression of NEDD8 in an in vitro model of adipogenesis was able to perturb expression of some key proteins involved in adipogenesis, such as C/EBPalpha and PPARgamma, possibly acting throughout the NEDD8/p27/beta-catenin pathway. Moreover, three out of five evaluated drugs were able to affect adipocyte differentiation: efavirenz, stavudine and saquinavir. Finally, we have shown that NEDD8 was expressed in the fat tissue of lipodystrophic patients, being significantly higher in the lipodystrophic patients with respect to the controls, thus further confirming the altered NEDD8 expression in the fat tissue of HIV-infected patients affected by lipodystrophy. Taken together, our data support the hypothesis of an implication of NEDD8 through p27 and beta-catenin pathways in the disruption of adipogenesis and consequent lipodystrophy in patients affected by HIV infection under HAART therapy with qualitative and quantitative differences according to diverse antiretroviral treatments. These evidences indicate the NEDD8/beta-catenin/p27 pathway as a possible molecular target for prevention of lipodystrophy development in patients under HAART therapy.
Asunto(s)
VIH-1 , Síndrome de Lipodistrofia Asociada a VIH/fisiopatología , Ubiquitinas/metabolismo , Adipocitos/citología , Fármacos Anti-VIH/farmacología , Ciclo Celular/efectos de los fármacos , Diferenciación Celular , Humanos , Proteína NEDD8 , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Ubiquitinas/genéticaRESUMEN
BACKGROUND: The present study aimed to investigate the role of stavudine in the onset of premature vascular lesions using an ultrasound color Doppler evaluation of the carotid vessels. PATIENTS AND METHODS: A total of 266 patients were evaluated: 149 were treated with stavudine (group I) and 117 without stavudine (group II). RESULTS: Of the patients in group I, 41% exhibited vascular lesions vs. 26% in group II (p=0.0103). The two groups were further divided into subgroups Ia (stavudine and proteinase inhibitor, PI), Ib (stavudine and non-nucleotidic reverse transcriptase inhibitor, NNRTI), IIa (PI, without stavudine) and IIb (NNRTI without stavudine). A higher prevalence of lesions emerged in group Ia, while group IIa were at higher risk of developing vascular lesions than groups Ib and IIb. CONCLUSION: Although stavudine per se does not seem to determine damage of the epiaortic vessels, the association of a PI with stavudine is related to a significantly higher rate of lesions.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Estavudina/uso terapéutico , Ultrasonografía Doppler/métodos , Enfermedades Vasculares/complicaciones , Enfermedades Vasculares/diagnóstico por imagen , Enfermedades Vasculares/tratamiento farmacológico , Adolescente , Adulto , Anciano , Niño , Femenino , Seropositividad para VIH , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
To obtain data on the evolution of carotid lesions, we evaluated 133 patients at their first antiretroviral regimen, followed for at least 2 years; 77 treated with protease inhibitors (PIs): Group A and 56 with non-nucleosidic reverse transcriptase inhibitors (NNRTIs): Group B. All patients were subjected to carotid ultrasonography. In Group A, among the previously normal patients 22.5% developed lesions, 40% remained normal, 37.5% shifted to other antiretroviral regimens. Among the 37 previously pathologic patients, 46% worsened, 19% were stable, in 8% the lesions had disappeared, 27% shifted. In Group B, among the previously normal patients, 12.7% developed lesions, 80.8% remained unaltered, 6.5% shifted. Among the previously pathologic patients, 12.5% worsened, lesions reversed in 25%, remained stable in 50% and 12.5% shifted to PI. At statistical analysis, in Group A both the percentage of patients developing new lesions and the percentage of patients who worsened was significantly higher. In conclusion, we evidenced a more rapid onset of lesions in patients treated with PIs with respect to patients treated with NNRTIs and towards a more rapid evolution of the previous lesions. The shift from PIs to NNRTI/3 NRTI seems related to a lower rate of evolution. Interestingly, a disappearance of lesions was detected in both groups.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Terapia Antirretroviral Altamente Activa/efectos adversos , Enfermedades de las Arterias Carótidas/inducido químicamente , VIH-1 , Adulto , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Femenino , Inhibidores de la Proteasa del VIH/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de la Transcriptasa Inversa/efectos adversos , Ultrasonografía Doppler en ColorRESUMEN
BACKGROUND: Various authors have hypothesized a role of Chlamydia pneumoniae infection in the pathogenesis of atherosclerosis. To better understand the possible role of this infection in the pathogenesis of epi-aortic lesions in HIV-1-positive patients, the presence of anti-Chlamydia pneumoniae antibodies was evaluated in a group of individuals subjected to ultrasonography of the epi-aortic vessels. PATIENTS AND METHODS: The presence of specific antibodies in 129 subjects was determined; 59 patients were HIV-1-positive, of whom 30 had carotid plaques and 29 were without lesions. The control group was composed of 70 subjects. All were subjected to ultrasonography of the epi-aortic vessels. IgG, IgM and IgA anti-C. pneumoniae antibodies were measured with micro-immunofluorescence and positive sera were tested for C. trachomatis and C. psittaci. RESULTS: No subjects were positive for IgM. Both the IgA and IgG levels did not differ significantly in the three groups. The only highly significant variable was the use of protease inhibitors. CONCLUSION: Our data suggest that the damage to the carotid wall in HIV-1 patients was not due to C. pneumoniae.